Klabaks - instructions for use, analogs, reviews and release forms (tablets 250 mg and 500 mg, including prolonged action of OD) of an antibiotic drug for the treatment of chlamydia, angina in adults, children and pregnancy. Composition and alcohol

In this article, you can read the instructions for using the drug Klabaks. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of experts on the use of Klabaksa in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Klabaks if there are existing structural analogues.Use to treat chlamydia, tonsillitis and pneumonia in adults, children, as well as during pregnancy and lactation. Composition and interaction of antibiotic with alcohol.

Klabaks - Semisynthetic antibiotic group of macrolides. Suppresses the synthesis of proteins in a microbial cell, interacting with the 50S ribosomal subunit of bacteria. Acts mainly bacteriostatically, as well as bactericidal.

It is active against Gram-positive bacteria: Streptococcus spp. (streptococcus), Staphylococcus spp. (Staphylococcus aureus), Listeria monocytogenes (Listeria), Corynebacterium spp .; Gram-negative bacteria: Helicobacter pylori (Helicobacter pylori), Haemophilus influenzae, Haemophilus ducreyi, Moraxella catarrhalis, Bordetella pertussis, Neisseria gonorrhoeae, Neisseria meningitidis, Borrelia burgdorferi; anaerobic bacteria: Eubacterium spp., Peptococcus spp., Propionibacterium spp., Clostridium perfringens, Bacteroides melaninogenicus; intracellular microorganisms: Legionella pneumophila, Chlamydia trachomatis (chlamydia), Chlamydophila pneumoniae, Ureaplasma urealyticum (ureaplasma), Mycoplasma pneumoniae (mycoplasma).

It is also active against Toxoplasma gondii, Mycobacterium spp. (except Mycobacterium tuberculosis).

Composition

Clarithromycin + excipients.

Pharmacokinetics

When administered orally, Clarithromycin is well absorbed from the digestive tract. Eating slows down absorption, but does not affect the bioavailability of the active substance. Clarithromycin penetrates well into biological fluids and body tissues, where it reaches a concentration 10 times greater than in plasma.It is excreted in the urine in unchanged form and in the form of metabolites.

Indications

Treatment of infectious-inflammatory diseases caused by pathogens sensitive to clarithromycin:

• infection of the upper respiratory tract and ENT organs (tonsillopharyngitis, otitis media, acute sinusitis);
• infection of the lower respiratory tract (acute bronchitis, exacerbation of chronic bronchitis, community-acquired bacterial and atypical pneumonia);
• infections of the skin and soft tissues;
• mycobacterial infections (M.avium complex, M. kansasii, M.marinum, M. leprae) and their prophylaxis in AIDS patients;
• eradication of Helicobacter pylori in patients with duodenal ulcer or stomach ulcer (only in combination therapy).

Forms of release

Tablets coated with 250 mg and 500 mg.

Tablets of prolonged action, coated with OD 500 mg.

Other dosage forms, be it suspension or capsule, do not exist.

Instructions for use and dosage

Tablets Klabaks

Inside.

The average dose for adults is 250 mg twice a day. If necessary, you can prescribe 500 mg 2 times a day. The duration of the course of treatment is 6-14 days.

Children prescribe the drug at a dose of 7.5 mg / kg 2 times a day. The maximum daily dose is 500 mg. The duration of the course of treatment is 7-10 days.

To treat infections caused by Mycobacterium avium, clarithromycin is prescribed by mouth 1 g 2 times a day. The duration of treatment can be 6 months or more.

In patients with renal insufficiency, with Cl creatinine less than 30 ml / min, the dose of the drug should be reduced by 2 times. The maximum duration of a course in patients of this group should be no more than 14 days.

Klabaks OD tablets

Inside, with food, not breaking, not chewing, swallowing whole.

Adults and children over 12 years of age - usually 500 mg once a day. In severe cases, the dose is increased to 500 mg twice a day.

The duration of treatment is 7-14 days.

Side effect

• nausea, vomiting;
• diarrhea;
• abdominal pain;
• stomatitis;
• glossitis;
• pseudomembranous colitis;
• cholestatic jaundice;
• dizziness;
• confusion of consciousness;
• feeling of fear;
• insomnia;
• nightmarish dreams;
• hives;
• anaphylactic reactions;
• Stevens-Johnson syndrome;
• temporary changes in taste.

Contraindications

• severe liver failure;
• hepatitis (in the anamnesis);
• porphyria;
• 1 trimester of pregnancy;
• simultaneous application with terfenadine, cisapride, astemizole, pimozide;
• increased sensitivity to clarithromycin and other antibiotics of the macrolide group.

Application in pregnancy and lactation

Application in the first trimester of pregnancy is contraindicated.

Application in the 2nd and 3rd trimester of pregnancy is possible only in cases where the intended benefit to the mother exceeds the potential risk to the fetus.

If necessary, use during lactation should stop breastfeeding.

Use in children

At present, there is insufficient data on the efficacy and safety of the use of clarithromycin in children under 6 months of age.

special instructions

Between antibiotics from the group of macrolides cross resistance is observed.

Treatment with antibiotics changes the normal flora of the intestine, so the development of superinfection caused by resistant microorganisms is possible.

It should be borne in mind that severe persistent diarrhea can be due to the development of pseudomembranous colitis.

With simultaneous application with clarithromycin, it is recommended to monitor the plasma concentrations of theophylline, carbamazepine, digoxin, lovastatin, simvastatin, triazolam, midazolam, phenytoin, cyclosporine and ergot alkaloids.

Periodic prothrombin time should be monitored periodically in patients receiving clarithromycin concomitantly with Warfarin or other oral anticoagulants.

Drug Interactions

Clarithromycin inhibits the activity of the isoenzyme CYP3A4, which leads to a slowing of the metabolic rate of astemizole when they are used simultaneously. As a consequence, there is an increase in the QT interval and an increased risk of ventricular arrhythmia such as pirouette.

With simultaneous use with atorvastatin, the concentration of Atorvastatin in the blood plasma is moderately increased, the risk of myopathy is increased.

With simultaneous use with warfarin, it is possible to increase the anticoagulant effect of warfarin and increase the risk of bleeding.

With simultaneous use with digoxin, a significant increase in the concentration of Digoxin in the blood plasma and the risk of developing glycosidic intoxication.

It is believed that an increase in the concentration of disopyramide in the blood plasma is possible due to the inhibition of its metabolism in the liver under the influence of Klabaks. There is a risk of prolongation of the QT interval, development of heart rhythm disturbances such as "pirouette", increased insulin secretion and hypokalemia.

With simultaneous application with zidovudine, the bioavailability of zidovudine decreases somewhat; with Itraconazole - significantly increases the concentration of itraconazole in the blood plasma, it is believed that there is a risk of increased side effects.

With simultaneous application with carbamazepine, the concentration of Carbamazepine in the blood plasma increases, there is a risk of increasing its side effect; with colchicine - cases of severe, life-threatening toxic reactions due to the action of colchicine are described; with lansoprazole - glossitis, stomatitis and / or the appearance of a dark color of the tongue are possible; with methylprednisolone - the clearance of methylprednisolone decreases; with midazolam - increases the concentration of midazolam in blood plasma and intensifies its effects.

With simultaneous application with omeprazole, the concentration of Omeprazole is significantly increased and the concentration of clarithromycin in the blood plasma is slightly increased.

With simultaneous use with pimozide, the concentration of pimozide in the blood plasma increases, there is a risk of developing severe cardiotoxic action; with Prednisolone - cases of development of acute mania and psychosis are described; with ritonavir - a significant increase in the concentration of clarithromycin,while the concentration of its 14-hydroxyclarithromycin metabolite is significantly reduced; with rifabutin - increases the concentration of rifabutin in the blood plasma, increases the risk of uveitis, decreases the concentration of clarithromycin in the blood plasma.

With simultaneous use with rifampicin, the concentration of Clabax in the blood plasma is significantly reduced; with sertraline - theoretically can not exclude the development of serotonin syndrome; with theophylline - it is possible to increase the concentration of theophylline in the blood plasma.

When used simultaneously with terfenadine, the rate of metabolism of terfenadine may be slowed down and its concentration in the blood plasma may increase, which may lead to an increase in the QT interval and an increased risk of ventricular arrhythmia such as pirouettes.

It is believed that with simultaneous application with tolbutamide, there is a possibility of developing hypoglycemia.

At simultaneous application with phenytoin it is possible to increase the concentration of phenytoin in the blood plasma, the risk of development of toxic action.

It is forbidden to use Klabaksa concomitantly with alcohol (the risk of developing hepatotoxic reactions is great).

At simultaneous application with Fluoxetine the case of development of the toxic effects caused by action of fluoxetine is described.

Inhibition of the activity of the CYP3A4 isoenzyme under the influence of clarithromycin leads to a slowing of the rate of cisapride metabolism when they are used simultaneously. As a result, the concentration of cisapride in the blood plasma increases and the risk of life-threatening heart rhythm disturbances, including ventricular arrhythmias such as pirouettes, increases.

When used simultaneously with cyclosporine, the concentration of cyclosporine in the blood plasma increases, there is a risk of side effects.

With simultaneous use with ergotamine, dihydroergotamine, there are cases of increased side effects of ergotamine and dihydroergotamine.

Analogues of the drug Klabaks

Structural analogs for the active substance:

• Arvitsin;
• Arvitsin retard;
• Binocular;
• Zimbactur;
• Kispar;
• Klabaks OD;
• Clarcat;
• Clarithromycin;
• Clarithrosine;
• Claricin;
• Claricite;
• Class;
• Clacid;
• Clerimedes;
• Coater;
• Crixan;
• Romiklar;
• CP Clarene;
• Fromromide;
• Fromyloid Uno;
• Ecositrin.

Similar medicines:

Other medicines: